Want to see HK:1521 full AI Analyst Report?
Frontage Holdings Corp. (1521) AI Stock Analysis
Frontage Holdings Corp.
(HKEX:1521)
Moderate financial performance with slowing growth and margin pressure is the primary factor capping the score, while positive technical momentum from price above moving averages provides support; high P/E valuation adds further downside risk.
Frontage Holdings Corp. (1521) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 3.03B
- Dividend Yield
- ―
- Average Volume (3M)
- 278.61K
- Price to Earnings (P/E)
- 36.6
- Beta (1Y)
- 0.31
- Revenue Growth
- 10.32%
- EPS Growth
- 178.23%
- Country
- Hong Kong
- Employees
- 1,800
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Frontage Holdings Corp. Business Overview & Revenue Model
Company Description
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequival...
How the Company Makes Money
Frontage Holdings Corp. makes money primarily through revenue earned from real estate-related activities. Key revenue streams typically include proceeds and margins from selling properties (including trading/flip-type transactions where the company a...
Frontage Holdings Corp. Financial Statement Overview
Summary
Moderate financial health with historical revenue growth slowing, declining margins, stable balance sheet, and improving cash flows.
Income Statement
45NeutralBalance Sheet
55NeutralCash Flow
60Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.95M | 256.69M | 254.91M | 259.86M | 250.36M | 184.44M |
| Gross Profit | 71.69M | 69.20M | 69.81M | 78.39M | 89.19M | 66.70M |
| EBITDA | 57.85M | 50.95M | 45.55M | 55.78M | 63.42M | 49.21M |
| Net Income | 10.60M | 6.79M | 791.00K | 10.81M | 25.73M | 18.43M |
Balance Sheet | ||||||
| Total Assets | 580.39M | 540.95M | 553.59M | 571.87M | 550.59M | 475.84M |
| Cash, Cash Equivalents and Short-Term Investments | 36.82M | 39.14M | 44.09M | 54.60M | 90.52M | 148.71M |
| Total Debt | 140.87M | 127.60M | 154.37M | 145.10M | 118.19M | 57.85M |
| Total Liabilities | 222.21M | 191.02M | 219.32M | 226.72M | 214.75M | 152.76M |
| Stockholders Equity | 354.84M | 346.74M | 333.00M | 342.50M | 333.08M | 319.84M |
Cash Flow | ||||||
| Free Cash Flow | 36.60M | 32.27M | 14.75M | 18.59M | 14.78M | -5.83M |
| Operating Cash Flow | 50.82M | 43.93M | 40.64M | 39.74M | 62.44M | 44.55M |
| Investing Cash Flow | -50.27M | -13.85M | -41.48M | -87.63M | -147.91M | -107.44M |
| Financing Cash Flow | -396.00K | -37.36M | -10.22M | 12.91M | 30.66M | -5.54M |
Frontage Holdings Corp. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1521, the sentiment is Positive. The current price of 1.49 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.24, and above the 200-day MA of 1.10, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 76.51 is Negative, neither overbought nor oversold. The STOCH value of 93.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1521.
Frontage Holdings Corp. Peers Comparison
Overall Rating
HK:226981Outperform
HK:154871Outperform
HK:231569Neutral- HK:152156Neutral
HK:682155Neutral
HK:375953Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2269 | 81Outperform | HKD 198.92B | 29.32 | 10.51% | ― | 21.93% | 21.94% |
| HK:1548 | 71Outperform | HKD 77.27B | -12.39 | -16.23% | ― | 53.48% | -120.02% |
| HK:2315 | 69Neutral | HKD 18.71B | 43.02 | 15.94% | ― | 48.04% | 166.72% |
| HK:1521 | 56Neutral | HKD 3.04B | 36.56 | 3.02% | ― | 10.32% | 178.23% |
| HK:6821 | 55Neutral | HKD 60.68B | 48.92 | 6.66% | 1.16% | 23.95% | 18.73% |
| HK:3759 | 53Neutral | HKD 89.64B | 50.48 | 10.93% | 0.76% | 24.21% | 19.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1521 | Frontage Holdings Corp. | 1.49 | 0.34 | 29.57% | |
| HK:1548 | Genscript Biotech Corporation | 33.68 | 17.67 | 110.37% | |
| HK:2269 | Wuxi Biologics (Cayman) | 48.68 | 14.90 | 44.11% | |
| HK:3759 | Pharmaron Beijing Co., Ltd. Class H | 30.40 | 6.91 | 29.39% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 42.98 | 14.98 | 53.50% | |
| HK:6821 | Asymchem Laboratories (Tianjin) Co., Ltd. Class H | 129.10 | 46.64 | 56.56% |
Frontage Holdings Corp. Corporate Events
Frontage Holdings Requests Trading Halt Ahead of Takeover-Related Announcement
Frontage Holdings has requested a trading halt in its shares on the Hong Kong Stock Exchange, effective from 9:00 a.m. on October 22, 2026. The suspension precedes the release of an announcement under Hong Kong’s Code on Takeovers and Mergers,...
Frontage Holdings Delivers Strong First-Half 2026 Profit Growth on Higher Revenue
Frontage Holdings Corporation reported solid growth for the six months ended June 30, 2026, with revenue rising 17.1% year-on-year to US$148.2 million and EBITDA increasing 17.4% while maintaining a stable EBITDA margin of 21.4%. Despite a slight dec...
Frontage Holdings Schedules Board Meeting to Review Interim Results and Dividend
Frontage Holdings Corporation has scheduled a board meeting for August 28, 2026 to review and approve the interim results for the six months ended June 30, 2026. The board will also consider whether to declare an interim dividend, a decision that cou...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026